ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
The sNDA seeks approval for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET). The application is based on the final results of the phase III CABINET pivotal trial, which showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) with cabozantinib versus placebo. A potential label expansion could boost sales of Cabometyx, which has already generated $1.3 billion in product revenues in the first nine months of 2024. Exelixis, Inc . EXEL announced that its supplemental new drug application (sNDA) for cabozantinib will be discussed at an Oncologic Drugs Advisory Committee (“ODAC”) meeting in March 2025. The sNDA is seeking approval for the drug to treat adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET). Exelixis' shares have surged 48.9% year to date against the industry's dec
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- EXEL vs. INCY: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
- Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024? [Yahoo! Finance]Yahoo! Finance
- Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Brookline Capital Management. They set a "buy" rating on the stock.MarketBeat
- Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 10/29/24 - Beat
EXEL
Sec Filings
- 12/23/24 - Form 4
- 12/2/24 - Form 4
- 11/29/24 - Form 144
- EXEL's page on the SEC website